An interventional study of Intervention group SOSteniamoci in Caregiver Burden, sponsored by Bar-Ilan University, Israel. Completed at 1 site in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-14.
Sponsored by Bar-Ilan University, Israel · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Caregiver Burden with a site in Italy — 3 open to participants now, 4 under way, none of them phase 3. Caregiver Burden · Italy.
Among the 10 studies in Caregiver Burden with a site in Italy, this one is one of 2 that started in 2022, is one of 9 with no phase, and was the 3rd registered.
503 studies on the registry are indexed under Caregiver Burden; 166 are open to participants now.
Browse Caregiver Burden studies →3 of the 10 studies in Caregiver Burden with a site in Italy are open now. Recruiting first, the newest first:
Azienda USL Reggio Emilia - IRCCS · Sites in Italy
Ages 18+
Istituto Nazionale di Ricovero e Cura per Anziani · Sites in Italy
Ages 65+
IRCCS Eugenio Medea · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 90 Caregiver Burden studies recruiting now, 69 (77%) set no upper age limit and 7 (8%) stop at 75 or younger; 8 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2022.
This study's enrollment of 105 is above the median of 73 across 404 interventional studies indexed under Caregiver Burden.
Median enrollment 48 across the 9 interventional studies, 213 across the 1 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 10 have an industry lead sponsor. The 9 most frequent:
Bar-Ilan University, Israel is the lead sponsor of 21 studies on the registry; 4 are open to participants now.
Bar-Ilan University, Israel has 1 study filed under Caregiver Burden — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Caregiver Burden with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate efficacy of internet intervention for informal caregivers in Italy in reducing their care-giving burden.
This intervention is going to take a form of an Internet-based Intervention (IBI) consisting of eight therapeutic modules. These are the themes, as listed chronologically: Introduction, Thoughts and Acceptance, Problem Solving, Stress and relaxation, Communication, Behavioural Activation, Worry and Anxiety, Maintenance. These themes were chosen after considering topics which might be the most useful for someone in a role of an informal caregiver, considering the trans-diagnostic nature of the intervention.
Effect of the intervention will be compared against a wait-list control group. Intervention is in Italian.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Trans-diagnostic, 8 module, 8 week long internet intervention for reducing informal caregiver burden
Behavioral: Intervention group SOSteniamoci
Participants in the control group will be instructed to wait. Once intervention group will be finished, participants in control group will be able to access the same intervention
Intervention based on cognitive behavioural therapy principles and culturally adapted to Italian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
Cargiver Burden Inventory (CBI)
This measure is used to evaluate caregiver burden. CBI contains 24 questions that are distributed within 5 facets - Time Dependency, Emotional Health, Development, Physical Health and Social Relationships. Answer options are presented on a 5-item Likert scale and ranges from from 0 ('Never') to 4 ('Nearly Always'). Total score on CBI is summed up and ranges from 0 to 96, higher score indicating higher levels of burden experienced.
Time frame: Pre-treatment; Week 8; 12 months post-treatment
Perceived Stress Scale (PSS-10)
Measure will be used to evaluate levels of experienced stress. It contains 10 questions on a Likert scale ranging from 0 ('Never') to 4 ('Very Often'). Higher score indicates more severe symptoms.
Time frame: Pre-treatment; Week 8; 12 months post-treatment
The Patient Health Questionnaire (PHQ-9)
Measure will be used to evaluate depressive symptoms. It contains 9 questions that must be responded to by choosing an answer from 4-item Likert scale, where number 0 indicates 'Not at all' and 3 - 'Nearly every day'. Higher score indicates more severe symptoms.
Time frame: Pre-treatment; Week 8; 12 months post-treatment
Generalized Anxiety Disorder (GAD-7)
Measure will be used to evaluate caregiver anxiety. GAD-7 contains 7 questions that must be responded to by choosing an answer from 4-item Likert scale, where number 0 indicates 'Not at all' and 3 - 'Nearly every day'. Higher score indicates more severe symptoms.
Time frame: Pre-treatment; Week 8; 12 months post-treatment
World Health Organization (WHO-5)
This questionnaire contains 5 statements regarding individual's well-being. Each of the statements must be evaluated using 6-item Likert scale with a score of 0 indicating 'At no time' while a score of 5 - 'All the time'. Higher score indicates higher well-being.
Time frame: Pre-treatment; Week 8; 12 months post-treatment
Couple Satisfaction Inventory (CSI-4)
This questionnaire contains 4 statements regarding couple satisfaction. Each of the statements must be evaluated using a 6-item Likert scale. A higher score indicates higher couple satisfaction.
Time frame: Pre-treatment; Week 8; 12 months post-treatment
The Inclusion of Illness in the Self Scale (IIS) - Caregiver version
This scale included a set of 7 pairs of concentric circles (one labeled 'Self' and one labeled 'Other's Illness') that vary in their degree of overlap from 1 (two separate circles) to 7 (almost completely overlapping circles).
Time frame: Pre-treatment; Week 8; 12 months post-treatment
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2022 to primary completion in Jul 2023, 12 months.
Of 285 non-industry interventional studies with no phase under Caregiver Burden, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's 12 months is below that.
Counting every sponsor, half of 294 studies reached it within 16 months; a quarter within 7 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bar-Ilan University, Israel